According to the National Cancer Institute: “A phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as turmeric, with a variety of pharmacologic properties. Curcumin blocks the formation of reactive-oxygen species, possesses anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation; and disrupts cell signal transduction by various mechanisms including inhibition of protein kinase C. These effects may play a role in the agent’s observed antineoplastic properties, which include inhibition of tumor cell proliferation and suppression of chemically induced carcinogenesis and tumor growth in animal models of cancer.” Over 240 published studies have appeared in the global scientific literature in the past year. Many researchers believe that curcumin’s multimodal effects act to simultaneously counter ten discrete causative factors in cancer development. It intervenes at each stage in the complex sequence of events that must occur in order for a cancer to develop, progress, invade, and ultimately metastasize to healthy tissue. The multi-targeted mechanisms of curcumin have yielded compelling results in combating a broad array of cancers, including those of the breast, uterus, cervix, prostate and gastrointestinal tract. According to the American Cancer Society, while “Human studies of curcumin in cancer prevention and treatment are in the very early stages,” nonetheless “A number of studies of curcumin have shown promising results. Curcumin can kill cancer cells in laboratory dishes and also reduces growth of surviving cells. Curcumin also has been found to reduce development of several forms of cancer in laboratory animals and to shrink animal tumors.” The National Cancer Institute at the National Institutes of Health currently lists 12 active and 10 closed clinical trials involving the use of curcumin in fighting cancer. The Bio-curcumin BM95 version of the extract chosen for the RECNAC formula has a proprietary delivery form of curcumin, is clinically supported via human trials in terms of efficacy and safety with a bio-availability level of approximately 7.5 times high as regular curcumin.